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Although  cultured  human  tumor cell lines have been shown  to be susceptible to 
lysis by a variety of immunologic effector mechanisms including natural killing (NK) 1 
and spontaneous  cell-mediated cytotoxicity (SCMC)  (1-7),  few instances of lysis of 
fresh uncultured  human tumor cells have been reported. When lysis of fresh human 
tumor cells was observed, it was present  in  only a  small percentage of the samples 
tested (8-11). Recently (12) we reported that peripheral blood leukocytes (PBL) from 
cancer patients could be activated in culture in preparations of interleukin-2  (IL-2), 
resulting in the development ofeffector cells cytotoxic for autologous fresh solid tumor 
cells in short-term 51chromium release assays in >90% of cancer patients tested. This 
paper further characterizes the IL-2-induced antitumor cytotoxicity phenomenon and 
provides evidence that it represents a previously unappreciated effector system distinct 
from the NK and the cytotoxic T  lymphocyte (CTL) systems. 
The IL-2-mediated activation of PBL to become cytotoxic to fresh autologous solid 
tumor cells  probably reflects  a  common  activation  mechanism  that  can  unify  the 
growing body of literature describing nonclassical cytotoxicities. Such reports include 
anomolous  cytotoxicities,  distinct  from  CTL  during  alloactivation  (13-17),  lectin- 
activated killing, distinct  from lectin-dependent killing (18), fetal calf serum culture- 
induced killers (16,  19-21), and mixed-lymphocyte tumor interaction (MLTI)-induced 
killers, found only when proliferation was stimulated (8-11, 22). Though fresh tumor 
targets were rarely used  in  those studies,  our previous reports of lysis of autologous 
fresh solid tumor cells after allosensitization  (23)  or lectin activation  (24), and those 
of others  after MLTI  (8-11),  support  this  hypothesis  and suggest  that  lymphokine 
activated killers (LAK) represent a unique and fundamental cytotoxic effector system 
that may play a  role in immune surveillance against NK resistant  solid tumor cells, 
and may have a  possible role in the adoptive immunotherapy of tumors. 
1  Abbreviations used in this paper: CTL, cytotoxic thymus-derived lymphocytes; CM, complete medium; 
DMSO, dimethyl sulfoxide; HBSS, Hanks' balanced salt solution; IF, immune interferon; IL-2, interleukin 
2; LAK, lymphokine-activated  killer cells; LBC, lymphoblastoid cells; MLTI, mixed lymphocyte tumor 
interactions; NK, natural killer; PBL, peripheral blood mononuclear leukocytes; PHA-P, phytohemagglu- 
tinin; SCMC, spontaneous cell-mediated cytotoxicity;  TCGF, T cell growth factor, C-TCGF, crude TCGF, 
PP-TCGF, partially purified TCGF; TDL, thoracic duct lymphocytes. 
Journal of Experimental Medicine • Volume 155, June 1982  1823-1841  1823 1824  LYMPHOKINE-ACTIVATED KILLER  CELL  PHENOMENON 
Materials  and  Methods 
PBL.  PBL were obtained  from normal  volunteers and cancer patients  by fractionation of 
peripheral  blood  cells on  LSM  gradients  (Litton  Bionetics,  Kensington,  MD)  as  previously 
described  (23).  The cells were washed  twice with  Hanks'  balanced  salt solution  (HBSS)  and 
resuspended  in complete medium  (CM) consisting of RPMI  1640 (Gibco Laboratories, Grand 
Island Biological Co., Grand  Island,  NY) containing  10% heat  inactivated human  AB serum 
(K.  C.  Biologicals,  Kansas  City,  MO),  100  U/ml  penicillin,  and  100  /~g/ml  streptomycin 
(National Institutes of Health [NIH] Media Unit).  PBL were used fresh or cryopreserved and 
subsequently thawed when needed. Blood from cancer patients was drawn before surgery or at 
least 2 wk after surgery. 
Fresh Tumor Targets.  Single-cell suspensions of fresh autologous tumor were prepared in one 
of two ways: 
FRoM MALICNANT  EFFUSIONS.  Fresh tumor cells were harvested in heparin  (I00 U/ml) from 
the ascites of a  patient  with breast  cancer.  The cell suspension  was washed  into HBSS three 
times at  100 g for 5 min, and the final cell pellet resuspended  in CM. 
FROM SOLID SURClCAL SPECIMENS.  Fresh-resected  tumor  was  collected  from  surgery  and 
transported  in  HBSS  at  4°C  until  processing.  Necrotic  tumor  and  connective  tissue  were 
removed, and the remaining specimen was minced, using scissors, in HBSS containing 5 U/ml 
hyaluronidase,  2  mg/ml  collagenase,  and  0.2-0.3  mg/ml  deoxyribonuclease.  The  fragments 
were  further  dissociated  by  trypsinization  by  mechanical  stirring  in  flasks  with  10-20  ml  of 
0.25%  trypsin  in  Dulbecco's phosphate-buffered  saline with EDTA without  calcium or mag- 
nesium  (NIH Media Unit) for  10 min. The resulting cell suspension was decanted  into a  tube 
containing  heat-inactivated  human  AB  serum,  and  the  trypsinization  repeated  with  the 
remaining fragments in the flask, adding more deoxyribonuclease if necessary. The cells in the 
total suspension were then pelleted and resuspended  in 20-50 cc of CM. Some specimens were 
processed further to eliminate contaminating lymphocytes according to the method of Kedar. 2 
A discontinuous gradient of 10 cc each of 25%,  15%, and  10% Percoll in CM was layered, and 
10 cc of the tumor cell suspension  was layered on top. The gradient was centrifuged at room 
temperature for 7 min at 25 g. The layers, bottom (tumor) and top (debris and unwanted cells), 
were  collected  separately,  washed  twice  with  HBSS,  resuspended  in  CM,  and  counted  for 
viability in  trypan  blue.  An  aliquot  was  sent  for cytologic analysis,  and  the rest  used either 
immediately or cryopreserved in 90% human AB serum plus  10% dimethyl sulfoxide (DMSO) 
for  future  use.  All  samples  were  analyzed  by  the  NIH  Cytopathology  Department  using 
Papanicolaou staining (25)  to determine the percentage of tumor cells. The tumor preparations 
used in the experiments reported in this paper are summarized  in Table I. 
Removal of Adherent Cells. PBL were incubated at 2 X  106/ml in CM in petri dishes for 1 h  at 
37°C.  Nonadherent  cells were recovered in the media after gentle swirling of the dish.  Each 
dish received one rinse with fresh CM, followed by swirling and aspiration of the nonadherent 
cells. Nylon-wool adsorption was performed for 1 h at 37°C in CM using scrubbed nylon wool 
(27). 
Serologic Depletion Studies.  Cells were washed twice in HBSS and resuspended at 4 X  106/ml 
in  HBSS  at  room  temperature.  The  previously determined  optimal  dilution  of monoclonal 
antibody  was  added  directly  to  the cells  (1:20  dilution  for OKT.3  and  OKT.8  from  Ortho 
Pharmaceutical  Corp.,  Raritan,  NJ; OKMI,  1:20 for 4F2 from Dr. A. Fauci, NIH; and  1:50 
for Leu-1 from Becton, Dickinson & Co., Sunnyvale, CA). Incubation was performed for 1 h at 
4°C with  occasional  mixing.  The cells were then  pelleted  by centrifugation,  and  the second 
antibody  (polyspecific rabbit  anti-mouse  immunoglobulin,  Cedarlane  Laboratories,  Ontario, 
Canada)  was added at a  1:10 dilution in HBSS. Incubation was continued for 30 min at 4°C. 
The cells were pelleted, and complement added  in HBSS. Newborn rabbit  serum was used as 
a source of complement and was found to be optimal at a  1:6 dilution. Complement lysis was 
performed at  37°C for  1 h, after which the cells were washed  twice in HBSS, resuspended  in 
CM, and counted for viability using trypan  blue. 
T  Cell Growth Factor (TCGF) Preparation and Partial Pur~cation.  Crude  TCGF  was  either 
purchased from Associated Biomedic Systems (Buffalo, NY) or prepared by us using a previously 
2 Kedar, E. A rapid technique for isolation of viable tumor cells from solid tumors.  Use of tumor cells for 
induction and measure of cell-mediated cytotoxic responses. Manuscript submitted for publication~ GRIMM  ET  AL. 
TABLE  I 
Patient- Tumor Systems Used 
1825 
Patient  Percent 
Patient  Tumor type  Processing 
Age  Sex  method*  malignant  cells 
6  52  F  Ovarian cancer  C  NT~ 
7  49  F  Aseites, breast cancer  A  82 
12  36  F  Osteosarcoma  C  50 
13  31  F  Stromal cell sarcoma  B  95 
14  69  M  Melanoma  B  94 
15  19  F  Osteosarcoma, metastases  B  40 
19  61  M  Melanoma  B  90 
23  20  M  Synovial cell sarcoma  B  67 
25  42  M  Synovial cell sarcoma  B  90 
30b  47  M  Melanoma  C  91 
30c  47  M  Melanoma  D  78 
36  42  M  Undifferentiated sarcoma  C  60 
37  42  F  Leiomyosarcoma  B  76 
41  40  F  Melanoma  C  72 
44  47  M  Melanoma  C  85 
45  24  M  Synovial cell sarcoma  C  90 
48  23  F  Synovial cell sarcoma  C  72 
51  20  F  Synovial cell sarcoma  C  65 
52  74  M  Pleomorphic liposarcoma  C  87 
53  39  M  Liposarcoma  C  50 
54  38  M  Synovial cell sarcoma  C  73 
56  58  M  Rhabdomyosarcoma  C  80 
57  38  F  Malignant fibrous histiocytoma  C  68 
58  17  F  Sarcoma  C  44 
59  78  M  Malignant fibrous histiocytoma  C  51 
63  56  F  Sarcoma  C  72 
64  24  M  Osteogenic sarcoma  C  29 
67  19  M  Sarcoma  C  68 
* Tumor processing methods used:  A, wash only;  B, collagenase,  hyaluronidase, deoxyribonuclease, and 
trypsin digestion, followed  by percoll  gradient; C, cell enzymes as in  (B), but no percoll  gradient; D, 
collagenase,  hyaluronidase, and deoxyribonuclease only.  All tumors were cryopreserved in  human AB 
serum containing 10% DMSO and stored in liquid nitrogen. 
Not tested. 
discussed modification (27)  of our original  method  (28).  In  brief,  PBL at  5  X  106/ml  were 
incubated in RPMI  1640 containing 2% human AB serum and 0.2% phytohemaglutinin (PHA- 
P)  (Difco Laboratories, Detroit, MI). The 2-d culture supernatant was collected by centrifu- 
gation and used as crude TCGF (C-TCGF). Partial purification and removal of the PHA from 
these C-TCGF preparations was performed as we described previously (29).  In brief, the C- 
TCGF was brought to 50% saturation with ammonium sulfate and the precipitate discarded. 
The  supernatant  was  then  brought  to  75%  ammonium  sulfate  saturation,  the  precipitate 
resuspended in  water to  achieve an  ~lA0  vol  of C-TCGF  starting sample, dialysed, first  vs. 
water then vs. phosphate-buffered saline, and passed over an affinity column (14 ×  0.9 cm) of 
Sepharose 4B  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden)  coupled  to  rabbit  anti-PHA 
antibody. Tests for TCGF activity were performed using TCGF-dependent human PBL after 
at  least  14  d  in culture.  Both short-term [ZH]thymidine uptake assays and  7-d growth assays 
were used to determine optimal TCGF titer (27-29). 
Lymphoblast (LBC)  Targets.  Lymphoblast cells were prepared by incubating fresh PBL at  1 
×  106/ml in CM with 10/xg/ml Con A  for 2 d. 
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NK-resistant lymphoma line were cultured in CM (containing human AB serum). These lines 
were passaged at 1:40 cell dilution every week. Repeated testing for mycoplasma contamination 
showed that both lines were negative. 
In  Vitro Sensitization and Partially Purified TCGF (PP-TCGF)  Activation of LAK.  Primary in 
vitro sensitization was  performed  by co-culture of responder PBL  with  stimulator PBL  in 
Falcon 3013 flasks (Falcon Labware, Oxnard, CA) incubated vertically in CM. Responder PBL 
were used at a final concentration of 1 ×  106/ml in CM. Irradiation of PBL stimulator cells was 
performed using a  laVcesium Source. (Isomedex Inc., Parsippany, N  J) at 2,000 rad. Stimulator 
cells were washed once after irradiation and added at  1 ×  106/ml. For generation of LAK, PP- 
TCGF was added to  1 ×  106/ml cultures of responder PBL at the dilution determined to be 
optimal for growth of TCGF-dependent cells (usually a  1:10 for the 10-fold-concentrated PP- 
TCGF). 
Measurement of Cytotoxicity  A 4-h 51Cr release assay was used to measure cytotoxicity of fresh 
tumor or PBL target cells. Target cells were thawed the morning of the assay, labeled with 400 
/~Ci of Na51CrO4  (Amersham Corp., Arlington Heights, IL) for 120 min in 0.5 cc of CM. The 
cells were then washed four times with CM and added at 5 ×  103 cells/well to various numbers 
of the effector lymphocytes in round-bottomed microtiter plates (Linbro Chemical Co., Ham- 
den, CT). The plates were centrifuged at 500 rpm for 3 min and incubated for 4 h at 37°C, 5% 
CO2. The culture supernatants were harvested with the Skatron-Titertek System (Skatron A.S., 
Lierbyen, Norway) and counted in a gamma counter. Maximum isotope release was produced 
by incubation of the targets with 0.1 N HC1. Spontaneous release was produced by incubation 
of targets with  CM  alone. Fresh tumor targets were  found to express between  10  and  30% 
spontaneous release during the 4-h assay. The percentage of specific lysis was calculated by the 
formula:  ([experimental cpm  -  spontaneous  cpm]/[maximal cpm  --  spontaneous cpm])  × 
100%. All determinations were made in triplicate and data are reported as the mean +  SEM. 
Results 
Fresh Solid Tumor Cells Are Resistant to Lysis by Autologous PBL Containing NK Cells, But 
Are Lysed by Autologous LAK Cells.  PBL  from  10 cancer patients were tested for lysis 
of the known NK sensitive target cell, K562, and the patients' fresh autologous tumor 
target cells (Table II). In the same experiment, the PBL were also activated with PP- 
TCGF  and tested for lysis against the fresh autologous tumor cells. In all 10 patients, 
fresh autologous tumor cells were lysed by the LAK cells. Also, fresh PBL from all 10 
patients demonstrated NK mediated lysis of K562, however, no significant lysis of the 
autologous tumor target cells was found by these same fresh PBL. These experiments 
demonstrated  that  fresh  PBL  from  cancer patients contain  NK  cells as defined by 
killing of K562 targets, but that these cells are incapable of causing detectable lysis of 
fresh tumor cells. All 10  fresh tumor samples were lysed by autologous LAK during 
the same 4-h 51Cr release assay. 
In  other experiments  we  found  that  LAK  were  generated  in  8  of  11  autologous 
combinations  (patients 6,  7,  12-15,  19, 25, 30,  36, and 37, data not shown).  In these 
experiments, lysis of autologous fresh PBL was also tested. Fresh PBL were lysed in 
four of eight combinations, but at a  much lower level than lysis of autologous tumor. 
The highest lysis of autologous PBL observed was half of the percent lysis of tumor. 
The 3 of 11  LAK-negative combinations were found to be caused by effector immune 
incompetence  in  2  cases  (patients'  PBL  were  unable  to  respond  in  an  in  vitro 
allosensitization, and  patients died within  2  weeks),  and  in one case the tumor was 
not lysable by any LAK  (neither autologous or allogeneic). 
In total, we have found that  18 of 21  (85%) autologous patient-tumor combinations 
are positive for LAK-mediated lysis of fresh tumor cells, and that 20 of 21  (95%)  fresh GRIMM  ET  AL. 
TABLE  II 
Lack of Autologous Fresh Tumor Lysis by Fresh PBL 
Percent specific lysis (± SEM) 
Patient  Fresh PBL  Autologous tumor 
(effector)/K562 











64.2  ±  0.5  -3.7 ±  2.4  89.8  ±  1.6 
46.3 ±  0.5  -1.0 ±  3.6  63.4  +  4.8 
19.0 ±  0.9  -1.6 +  7.6  37.3 :tz 4.6 
44.0  ±  0.4  --0.9 ±  0.2  44.1  ±  2.3 
26.3 ±  1.3  --0.8 ±  0.2  34.1  ±  1.8 
NT§  NT  22.3  +  1.4 
22.2 +  0.2  2.0 -I- 1.6  51.4 ±  2.8 
8.6 ±  0.2  0.0 ±  1.1  40.4  +  2.0 
1.6 +  0.2  3.4 +  0.6  16.3 ±  0.8 
14.0 +  0.8  --3.6 +  0.4  30.0 ±  0 
4.0 ±  0.7  --1.7 ±  0.6  21.0 ±  1 
1.0 ±  0.4  1.6 ±  1.1  13.0 ±  1.0 
24.1 ±  0.0  2.4 ±  1.8  24.6 +  1.9 
14.9 ±  0.8  3.7 ::t: 2.5  9.3 ±  0.4 
7.3 +  0.8  1.8 ±  0.2  4.8 ±  0.1 
24.6 ±  2.2  -3.2 ±  3.2  38.6 ±  8.9 
7.5 ±  0.0  3.4 ±  4.0  19.2 +  7.2 
1.7 ±  0.3  3.9 ±  0.9  6.1  ±  8.3 
27.8 ±  1.2  --7.9 ±  0.4  50.2  +  0.7 
11.4-1- 1.1  --3.4±  1.0  14.6-1- 1.2 
3.3 ±  0.4  1.8 ±  3.7  5.1  ±  1.1 
59.9  ±  3.3  -5.4 ±  0.6  27.5 +  4.7 
27.3 +  0.5  0.4  ±  5.6  18.4 ±  0.7 
8.8 +  0.4  --4.4 ±  2.7  3.5 ±  1.6 
39.3 +  0.3  --0.6 +  0.8  43.0  ::t: 1.4 
14.4 ±  0.2  5.6 +  4.3  26.2  +  3.4 
3.8 ±  0.2  1.9 ::t: 0.8  7.6 +  0.4 
34.9  ::t: 0.9  1.0 ±  1.0  16.1 :t:: 1.1 
14.5+0.7  --3.6-t-  1.1  11.5-t-  1.9 
4.7 +  0.1  2.8 ±  0.9  7.2 +  0.9 
* Fresh PBL were used at effector/target ratios of 100:1, 25:1,  and 6:1. 
PBL were cultured in CM with 10% PP-TCGF to produce LAK, which 
tested for lysis at effector/target ratios of 40:1,  10:1, and 2.5:1. 
§ Not tested. 
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tumors  are  lysable  by  LAK  (either  autologous  or allogeneic,  see  Figs.  1  and  2),  but 
that  no  (0 of 10)  fresh autologous  tumor  cells are lysed by autologous  NK. 
Fresh Solid  Tumor  Cells Are  Resistant  to  Lysis  by Fresh NK-containing  PBL of Normal 
Individuals.  The  data  in Table  II show that  PBL  from cancer  patients  expressed  NK 1828  LYMPHOKINE-ACTIVATED KILLER  CELL  PHENOMENON 
Fro.  1.  Fresh solid tumor ceils are NK resistant and LAK sensitive.  The combined data from two 
4-h S~Cr release assays is depicted.  13 uncultured solid tumor samples were tested as targets for their 
susceptibility to lysis by NK-containing PBL of 17 normal individuals, at an effector/target ratio of 
150: I. The normal individuals consisted of eight females and nine males, and ranged in age from 19 
to 41.  PBL from the first eight individuals were tested in both experiments. Lysis was considered 
positive when the percent specific  lysis was statistically significant at the P ~  0.01 level  using the 
Student's t test.  Activated PBL are normal PBL from patients 7 and  12 cultured in PP-TCGF for 
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Fic.  2.  LAK lyse allogeneic fresh tumor cells.  PBL from melanoma patient  14 were activated  by 
culture  in  PP-TCGF  for  7 d  and  tested  for LAK-mediated  lysis  of fresh autologous tumor and 
autologous PBL as well as allogeneic PBL and allogeneic tumor 15. Data are shown for the effector/ 
target  ratio of 20:1.  Tu,  tumor;  1,  autologous melanoma;  2,  allogeneic  melanoma;  3,  allogeneic 
osteosarcoma. GRIMM ET AL.  1829 
activity toward K562 but  did not express detectable NK activity toward their fresh 
solid tumor cells. However, it remained possible that fresh tumor cells were sensitive 
to  lysis  by subpopulations  of NK  cells  deficient  in  cancer  patients.  Therefore,  to 
determine whether fresh tumor cells were sensitive to any NK-mediated cytotoxicity, 
we  tested  PBL  from  17  normal  individuals  for lysis of K562  and  for lysis of fresh 
allogeneic solid tumor cells (Fig.  1). 
All tumors were sensitive to lysis by the LAK (26 of 26 tests)  and all normal PBL 
contained high levels of NK activity in 25 of 25 tests directed against  K562 targets. 
However, only 6% of the normal PBL-fresh tumor combinations (15 of 239) displayed 
significant lysis of the solid tumors, and of those tested a second time, only 2 of 6 were 
lyric. Of the 13 solid tumor preparations tested, 8 were lysed by PBL from any normal 
individual, and 3 were lysed by PBL from only a single donor. Two tumor preparations 
(numbers 41  and  45)  were lysed by the PBL from 5  of the  17  donors.  15 of the  17 
normal PBL lysed none or only 1 of tumor specimens;  1 donor (patient  15) lysed 2 of 
the  10 tumor targets and  1 donor (patient 5)  lysed 4 of the  13 targets tested. 
A Mantel-Haenszel stratified analysis (30)  revealed that the lysis of fresh tumor by 
fresh  PBL was significantly  less  (P <  0.0001)  than  their  lysis by the  LAK.  A  chi- 
square analysis for multinomial  observations  (31)  showed  that  the susceptibility of 
fresh tumors to lysis by fresh PBL was not normally distributed,  with some tumors 
more susceptible than expected  (P =  0.0025).  Using the same statistical  test, it was 
also determined  that  the normal PBL population appeared skewed, with PBL from 
one  normal  individual  (patient  5)  expressing  a  level of killing  not  expected  to  be 
observed by chance  alone  (P =  0.0009);  therefore,  it  is  possible that  some normals 
(-5% based on our 1 of 17) do contain killer cells circulating in their PBL capable of 
killing fresh  tumor.  Though  these chi-square  analyses suggest  that  fresh  PBL from 
some normals are capable of killing fresh tumor, and that some tumor cells are more 
susceptible to lysis than others, the main conclusion is that LAK-sensitive fresh solid 
tumor cells are in general insensitive to lysis mediated by NK cells. 
The resistance of uncultured human solid tumor cells to NK and their susceptibility 
to LAK is not due to any processing artifact of the tumor cells. Most of the target cells 
used for the experiments in Table II and Fig.  1 were prepared by enzymatic digestion 
from the connective  tissue  and  ground  substance,  using  a  cocktail of enzymes (see 
Materials  and  Methods)  including  trypsin.  Our  results  show  that  this  enzymatic 
treatment neither creates nor destroys the antigenic determinant(s)  recognized by the 
LAK,  because  a  tumor  from patient  7,  malignant  ascites  in  a  patient  with  breast 
carcinoma, received no enzymatic processing and was easily killed by LAK, and not 
by NK. Melanoma tumor 30b was prepared by using hylauronidase, collagenase, and 
deoxyribonuclease, but  not  by trypsin, and was also not  lysed by the NK cells, but 
was lysed by the LAK. Trypsinization of K562 cells does not affect their lysis by NK 
cells (32). 
These experiments demonstrated  that  PBL from normal individuals  contain  NK 
cells as evidenced by lysis of K562 target cells, but that these whole PBL populations 
are incapable of lysing the great majority of fresh allogeneic tumor cells. Thus, LAK 
lysis of uncultured  tumor cells is not unique to cancer patients, and therefore cannot 
be considered  as a  specific anamnestic response, because PBL from normal, tumor- 
free individuals can be induced to express this activity. 
Fresh Tumor Cells Are Lysed by Allogeneic LAK from Cancer Patients and Normal Individu- 1830  LYMPHOKINE-ACTIVATED KILLER CELL  PHENOMENON 
als.  As shown  in  Fig.  1,  allogeneic normal  LAK cells were  capable of lysing fresh 
tumor from all fresh tumor specimens tested. To further study this phenomenon, PBL 
from melanoma patient  14 were cultured for 7 d  in PP-TCGF and then tested for the 
expression of LAK activity toward the autologous tumor and PBL and to an allogeneic 
melanoma  and  an  allogeneic  osteosarcoma  and  PBL  (Fig.  2).  It  was  found  that 
allogeneic fresh tumor, but not allogeneic PBL, was lysed. Therefore, the PP-TCGF- 
induced lysis of allogeneic tumors represents LAK that preferentially kills tumor cells, 
and  not  usually  the  corresponding  PBL,  suggesting  that  LAK  lysis of allogeneic 
tumors is not merely an allogeneic response. Lotze et al. (12) reported that allogeneic 
cultured tumors and fibroblasts were also lysed by TCGF  activated PBL. Therefore, 
LAK killing is not  restricted to autologous tumor cells or to single histologic tumor 
types, but is expressed to allogeneic fresh and cultured lines, implying that the target 
specificity is broad. 
Autologous PP-TCGF Stimulates  LAK  Lytic for  Autologous Tumor.  To  test  whether 
allogeneic  PP-TCGF  was  required  for  LAK  generation  (allogeneic PP-TCGF  was 
used  in all other experiments in  this paper)  and  whether  PBL  from cancer patients 
were  competent  to  generate  TCGF  suitable  for  LAK  activation,  we  prepared  PP- 
TCGF  by PHA stimulation of PBL from melanoma patient  14. Culture of fresh PBL 
from patient  14 with his autologous PP-TCGF did generate LAK (Table III). Patient 
14 was known to have a  moderate tumor burden at the time of his leukophoresis, and 
died ~6 mo later. Thus,  PBL from cancer patients are competent to produce TCGF. 
Autologous  TCGF  stimulates  LAK,  thereby  ruling  out  the  possibility that  LAK 
stimulation depends on an allogeneic effect. 
Immune Interferon (IF) Is Not the Primary Stimulus in PP-TCGF.  Interferon has been 
shown  to  augment  NK  activity  and  to  stimulate  lysis  of  allogeneic  but  not  of 
autologous fresh tumors (33, 34). Because IF is known to be present in PP-TCGF, we 
tested whether IF and not IL-2, as presumed, was the primary stimulus for LAK. To 
examine this, we tested for LAK development in PP-TCGF depleted of IF by exposure 
to  acid  pH.  Table  IV  shows  that  the  IF-depleted PP-TCGF  was  fully capable  of 
TABLE III 





Percent specific lysis of autologous 
Tumor  PBL 
1:4  40:1  27.7 +  1  15.7 + 2.8 
10:1  16.6 ± 0.4  8.5 ±  1.1 
2.5:1  5.2 + 0.7  -3.0 + 0.2 
1:8  40:1  28.0 + 20  -4 +  1 
10:1  14.0+0.4  -2+  1 
2.5:1  4.8 + 0.1  -- 
No PP-TCGF  40:1  0.2 ± 0.7  -3 ± 2.7 
10:1  -9 ± 0.2  -8 ±  1.0 
* PBL from melanoma  patient  14 were collected by leukophoresis, and PP- 
TCGF prepared and tested exactly as from normal PBL. A fresh salnple of 
PBL from patient 14 was then collected and cultured in his autologous PP- 
TCGF  for  7 d.  The cultures  were  then  tested  for LAK activity toward 
autologous tumor and PBL. GRIMM  ET  AL.  1831 
TABLE  IV 
Interferon-depleted PP-TCGF Maintains Stirnulatory Activity 
Percent specific lysis of autologous* 
Tumor 37  PBL  37 
PP-TCGF, 630 U/ml:~  28.9 ::!: 2.3  3.5 +  2.4 
10.8 +  1.8  2.3 +  2.8 
3.8 +  0.9  -2.5 -  0.8 
PP-TCGF, <5 U/ml~§  26.8 +  4.3  1.2 +  0.3 
18.0 ::t: 0.0  0.2  :t: 0.2 
13.2 +  4.8  0.6  +  1.9 
* Effector/target ratios used were 40:1,  5: l, and  1.25:1. 
Determination  of leukocyte  interferon  units  was  performed  by  Biofluids, 
Rockville, MD, courtesy of Dr. John Ortaldo, National Cancer Institute. 
§ Interferon  was  denatured  by  an  8-h  dialysis  vs.  glycine-HCI  at  pH  2.0, 
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Fro.  3.  Kinetics of LAK development. PBL from leiomyosarcoma patient 37,  melanoma patient 
14, and sarcoma patient 52 were cultured in PP-TCGF and tested for lysis of autologous tumor on 
the days shown. Patient  52  LAK were also tested for lysis of an allogeneic melanoma tumor 30 b. 
All assays were for 4 h at effector/target ratios shown. 
generating  LAK.  Therefore,  a  factor(s)  in  PP-TCGF  other than  IF  is  the  primary 
stimulus for LAK. 
Kinetics of LAK Development.  Because  fresh  PBL  from cancer  patients  or normal 
individuals  did  not lyse fresh autologous or allogeneic tumor cells  (Table  I and Fig. 
I),  but  did  exhibit  this  lysis  after  7  d  in  culture  in  PP-TCGF,  we  investigated  the 
kinetics  of the  development  of LAK  lytic  activity.  PBL  from three cancer patients 
were cultured  in  PP-TCGF  and assayed  for tysis of autologous tumor target  cells at 
various times (Fig.  3).  PBL from one patient was also tested for lysis of an allogeneic 
tumor. In all  tests,  lytic activity was evident  by day 3,  and in the one combination 10(3 
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Fic. 4.  Kinetics  of development and specificity of LAK lysis. PBL from patient 37 were tested for 
lysis of autologous tumor (also shown in Fig. 3), and for the development of lysis to other target 
cells. All tests were performed in parallel in a 4-h assay, and the data shown are for an effector/ 
target ratio of 50:1. A, autologous PBL; O, autologous Con A lymphoblasts; ZX, allogeneic PBL; 
l-I, autologous tumor; 0, K562; 0, Daudi. 
tested,  a  low level of lysis was evident on day 2. In data not shown, no lysis was ever 
detected on day  l. LAK lysis of tumor cells continued to increase to day 5 in three of 
four cases.  Therefore,  it  can  be concluded  that  LAK are  evident  by day  2  or 3  of 
culture  in PP-TCGF and persist  at  least  until  day 7. Our previously published  data 
(12) showed that lysis of autologous tumor was expressed as long as 14 d  after culture 
in  PP-TCGF,  and  preliminary  cloning  experiments  revealed  that  LAK  activity 
persisted even longer, but that not all TCGF stimulated clones expressed LAK activity 
(data not shown). 
In two of the  patients  tested  for kinetics  of development  of LAK cells,  other cell 
types were also used as targets. The results from patient  37 are shown in Fig. 4. At no 
time was cytotoxicity expressed toward the autologous PBL, Con A  lymphoblasts, or 
to allogeneic  PBL;  however,  cytotoxicity to  the  autologous tumor  and  to  the  NK- 
resistant, cultured lymphoma line, Daudi, developed in parallel.  NK activity to K562 
was clearly positive in the fresh PBL, but did increase in parallel with the development 
of LAK. It is reported  (35)  that highly enriched NK populations grow in TCGF, and 
their  persistence  in  culture  along  with  the  LAK-mediated  lysis  toward  K562  after 
days  2  and  3  can  be  responsible  for the  cumulative  cytotoxicity expressed  toward 
K562. 
Proliferation of PBL Is Required  for LAK Expression.  Because  LAK cytotoxicity was 
evident  early  (days  2  and  3),  we questioned  whether  the  initial  expression  of LAK 
required  proliferation  of the  PBL.  PBL from three  patients,  irradiated  at  2,000 rad, 
were therefore tested  for PP-TCGF-induced  LAK development  (Table V).  Whereas 
the nonirradiated  PBL consistently developed LAK, the irradiated  PBL did not, even 
though viable cells were recovered from the cultures and the cultures were tested on 
days 3  and 4. Therefore,  it  is concluded that an irradiation-sensitive,  differentiation 
phase is required  for LAK expression.  Although LAK populations  appear heteroge- 
neous at the light-microscope level, they do contain blastic appearing lymphoid cells, 
showing evidence of activation. 
Precursors of LAK Are Not  Cells and Are Nonadherent.  To  determine  if LAK could GRIMM  ET  AL. 
TABLE  V 
Induction of LAK Is Radiation Sensitive 
1833 
Autologous PBL 
Percent cytotoxicity  of autologous tumor 
44  57  4.6 
Irradiated 
Nonirradiated 
E/7~  E/T  E/T 
40:1  9.3 ±  4.0  40:1  7.8 ±  4.4  50:1  --4.5 +  2.5 
10:l  2.8__.  1.3  10:1  --0.8 ±  0.9  12.5:1  --2.4±5.5 
2.5:1  --5.2+3.1  2.5:1  --3.7±0.8  3.1:1  7.8__.8.2 
40:1  89.8 +  1.6  40:1  50.2  ±  0.7  50: l  23.0 ±  0 
10:1  63.4 ±  4.8  10:1  14.6 _  1.2  12.5:1  8.1  ±  1.2 
2.5:1  37.3±4.6  2.5:1  5.1  ±  1.~  3.l:1  -0.4+2.8 
* Fresh PBL from each patient were either irradiated (2,000 rad), or not irradiated, followed by culture in 
PP-TCGF.  Lysis of the autologous tumor was tested in a  4-h  ~lCr release assay. Culture was 3  d  for 
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FIo.  5.  TDL  void of NK activity are stimulated to express LAK activity. Early TDL  drainage 
from three noncancer patients being prepared for kidney transplantation were washed and purified 
as described for PBL. To stimulate LAK activity, the TDL were cultured for 7 d  in CM containing 
PP-TCGF, and then tested for lysis of melanoma tumor 44. 
represent  a  form of "activated NK" cell, we examined whether  fresh thoracic duct 
lymphocytes (TDL), known to be void of NK cells (36), would respond to PP-TCGF 
and develop antisolid tumor lytic activity. Fig. 5 confirms that fresh TDL from three 
different  patients  are devoid of anti-K562  NK activity, but  that  LAK did  develop 
from these TDL. In the same assay, the K562 target cells were lysed by fresh PBL, as 
expected. Therefore, LAK precursors do not express NK activity and are most likely 
not classical NK cells. 
Depletion of plastic- and nylon wool-adherent cells from PBL had no effect on the 
generation of LAK (Table VI). Depletion of adherent cells from PBL was performed 
in  12 experiments with a cell recovery from 33 to 77%,  with a  mean of 56.2%.  In all 
experiments, no decrease, and an occasional augmentation in the generation of LAK, 
were found. Wright-Giemsa stb.ining of the plastic culture plates after PBL adherence 
confirmed  that  monocytes did  adhere,  and  after  the  nylon-wool  incubation,  the 
resulting cells were >79% lymphocytes. Because no decrease in the generation of LAK 
was evident, it appears that LAK precursors are neither monocytes nor B lymphocytes. 
Our  data  strongly  suggest  that  adherent  cells  are  unnecessary  in  LAK activation, 1834  LYMPIlOKINE-ACTIVATED KILI,ER CELL  PItENOMENON 
TABLE  VI 
Precursors of LAK Are Nonadherent PBL 
Starting population 
Percent specific lysis* 
Tumor  PBL 
Whole PBL  50.4 ± 2.9  14.7 ±  1.5 
28.5 + 2.8  4.5 ____. 1.6 
12.5±2.6  0.1 ±0. l 
Nonadherent  PBL:~  53.4 +  1.7  22.9 + 3.1 
39.4 -  1.8  9.4 ±  1.8 
13.9 + 2.2  -2.2 +  1.l 
* Lysis ofautologous tumor and PBL was performed in a 4-h '~lCr  release assay 
at effector/target  ratios of 20: 1, 5:1, and 1.25:1. 
:~ Nonadherent  cells were  recovered  after  1 h  of plastic-plate adsorption, 
followed by 1 h of nylon-wool adsorption  at 37 ° as described in Materials 
and Methods. In this experiment,  70% of the PBL were recovered from the 
procedure and then cultured in PP-TCGF for 7 d. 
however,  they  do  not  rule out  a  role for a  minimal number  of adherent  cells in  an 
accessory function. 
LAK  Effectors  Are  Nonadherent  and  Express  Serologically  Detectable  T  Cell  Markers. 
Because  LAK effeetors are recovered from  plastic tissue culture flasks, it  was  likely 
that  they  were  nonadherent  to  the  plastic  of the  flask.  However,  to  establish  the 
nonadherent  nature  of the  LAK, effector populations were  incubated  on  scrubbed 
nylon wool columns for 1 h  at 37°C immediately before the 51Cr release assay. Neither 
autologous nor allogeneic LAK activity were eliminated by the nylon wool adherence, 
although significant numbers of cells were retained by the columns (data not shown). 
A  variety of monoclonal antibodies were used for detection of serologieally defined 
markers on  LAK  effector cells using complement-mediated  lysis (Table VII).  LAK 
activity was found to be significantly diminished by antibodies defining T  cell markers 
OKT.3  (37),  Leu-1  (38),  and  4F2  (39),  but  not  the  monocyte  and  NK  marker, 
OKM-1  (40,  42).  However,  the  depletion  was  not  total.  Attempts  using  various 
dilutions  of antibodies or  complement,  both  with  and  without  a  second  antibody, 
have  failed to achieve a  total  depletion of lytic activity. Therefore we repeated  the 
depletion of LAK  effectors by  the T-specific OKT.3  and  OKT.8  (cytotoxic T  cell 
marker)  (42)  antibodies  in  parallel  with  depletion  of  CTL  tested  against  PBL 
expressing  the  specific alloantigen  as  a  positive  control  for  depletion  of a  known 
effector function.  The  OKT.3  and  OKT.8  complement-mediated treatment  dimin- 
ished, but  did not eliminate CTL  activity (data not shown).  Again these antibodies 
diminished but did not totally eliminate LAK activity. Therefore, the LAK effectors 
are as sensitive to OKT.3  and OKT.8  as are CTL  using our complement-mediated 
lysis technique.  We  believe that  our  technique  was  optimal,  but  that  the  reagents 
were not as sensitive for the complement-mediated detection of antigens as has been 
reported using fluorescence techniques (37-42) and that LAK do express markers that 
are in common with CTL and activated T  cells. 
Discussion 
This  paper describes the human  LAK phenomenon  as distinct  from  the NK and 
CTL systems (summarized in Table VIII). Major features of the LAK system include: GRIMM  ET  AL.  1835 
TABLE  VII 
Serologic Profile of LAK Effector Cells 
Treatment of LAK effector cells*  Total  Percent specific  Lytic  lytic 
Percent  lysis of tumor  units per 
Antibody  Comple-  cells re-  63:~  106 cells  units re- 
ment  covered¶  covered§ 
100  78.6 4- 2.1  21.3  21.3 
48.4 4- 1.8 
15.9 + 0.8 
+  i00  85.2 4- 6.3  30.0  30.0 
54.7 +  5.4 
24.4 +  2.2 
OKM.1  +  100  79.3 +  2.2  22.0  22.0 
43.1 +  1.3 
13.4 + 0.2 
OKT.3  +  71  56.7 4- 3.8  11.l  7.9 
24.5 + 0.5 
9.1 :lz 1.1 
Leu-1  +  11  54.4 4- 1.1  10.0  1.1 
24.0 +  2.6 
6.0 --. 1.8 
4F2  +  100  43.3 +  1.2  7.7  7.7 
22.3 + 0.8 
10.7 4- 2.1 
* LAK were prepared from PBL by culture for 3 d in PP-TCGF. 
~: Lysis was tested at effector/target ratios of 50:1, 12.5:1, and 3:1. 
§ Lyric units per 106 cells (106 divided by the number of cells required to cause 
33.3% lysis of 5 ×  104 tumor cells), corrected for the number of cells recovered 
after treatment. 
¶ Percentage of cells recovered determined by trypan blue exclusion counts for 
viable cells. 
(a)  LAK  lyse NK-resistant  fresh solid tumor cells in a  4-h 51Cr release assay;  (b)  LAK 
can  be  generated  by  a  2-3-d  culture  in  IL-2  containing  supernatants,  from  either 
allogeneic  or  autologous  sources;  (c)  IF  is  not  the  primary  stimulus  responsible  for 
LAK;  (d)  neither precursors  nor LAK  effectors are adherent  cells;  (e)  LAK  precursors 
are  found  in  NK-void  TDL  populations,  as  well as  in  normal  and  cancer  patients' 
PBL;  (f)  LAK  development is radiation  sensitive; and  (g)  LAK  effectors express the 
serologicaUy  defined  phenotype  of T  cells.  The  kinetics  of development  shows  that 
LAK  cells  are  generated  after  several  days  of in  vitro culture  with  PP-TCGF.  The 
kinetics of development  and  the stimulus required serve to distinguish  LAK  from the 
CTL  system. The development of LAK expression is much faster than that of primary 
CTL,  but  is not different from that of secondary CTL.  PBL from normal individuals, 
however,  can  be induced  to kill tumors  by exposure  to  IL-2, indicating  that  LAK  is 
probably  not  an expression  of classical secondary  CTL  from memory  populations.  A 
further  indication  distinguishing  the  LAK  system  from  CR  is  the  observation  that 
depletion  of OKT.3-positive  cells  from  fresh  PBL,  followed  by  activation  with  PP- 1836  LYMPItOKINE-ACTIVATED KILLER CELL PHENOMENON 
TABLE VIII 
LAK Mediated Antisolid Tumor Killing Represents a Previously Undefined Lytic System 
Characteristic 
I,ytic Activity 
NK  LAK  CTI, 
Development kinetics  Fresh PBI.  Day 2, 3  Day 5, 6 
Stimulus  None  IL-2 (or cellular interac-  Specific  antigen 
tions generating IL-2) 
Specificity of cytotoxicity  Bone marrow; cultured 
cells; leukemia 
Fresh solid tumors  (plus 
all  targets  killed by 
NK) 
Specific antigen 
Precursor location  TDL-  TDL+  TDL Unknown 
PBL+  PBL+  PBL+ 
Serologic Phenotype of  OKM. l +  OKM. 1  -  OKM. l- 
effector  OKT.3-  OKT.3+  OKT.3+ 
TCGF, greatly augmented  LAK production  (E. A. Grimm, A. Mazumder, and S. A. 
Rosenberg,  manuscript  in preparation),  indicating  that  the  LAK precursor  is  not  a 
mature T  cell. 
The kinetics of LAK generation is reminiscent of the kinetics of development of the 
anomolous  killing  of NK-resistant  cultured  tumors  described  by Seeley  and  Golub 
(13),  because  lytic activity toward  NK-resistant  lines was evident  2-3 d  earlier  than 
CTL  during  an  allosensitization.  The  LAK  killing  system  is  probably  the  final 
common  pathway  that  explains  many  of  the  nonclassical  cellular  cytotoxicities 
reported previously, though fresh tumor cells were usually not used as target cells in 
such studies. These reports include activated cell ~killing (16), fetal calf serum-induced 
killing (19-21), and lectin-stimulated killing (18). Previous reports from our laboratory 
support the hypothesis that LAK may be generated from primary stimuli other than 
IL-2,  but  in  which  IL-2 is  also  generated,  such  as  during  allosensitization  (23)  or 
during  lectin  activation  with  T  ceil  mitogens  (24),  because  in  our reports,  effectors 
were generated that did kill fresh autologous solid tumor cells. Therefore, the stimulus 
for production of LAK cells may be found during a  variety of culture conditions, all 
of which are known to involve IL-2 production  (27). 
The stimulus  required  for LAK generation  further  serves to distinguish  the  LAK 
from  the  NK  and  CTL  systems.  No  stimulus  is  known  to  be  required  for  NK 
generation,  though presumably a  signal exists for NK differentiation  in vivo. Leuko- 
cyte  interferon  is  considered  as  a  potent  stimulus  for  NK  augmentation,  but  was 
found not  to be the primary stimulus  in  PP-TCGF for LAK development.  NK cells 
are  apparent  in  fresh  PBL  without  exogenous  stimulation,  whereas  LAK cells  do 
require  exogenous  stimulation  and  proliferation  to be  expressed.  CTL  require  two 
signals: a proliferative stimulus, and a specific antigenic stimulus.  We have previously 
shown that our PP-TCGF contains the factor(s) that synergize with nonimmunogenic 
alloantigen  to induce a  competent  in vitro sensitization  toward alloantigen,  but that 
the  PP-TCGF  culture  of responder  PBL  alone  in  PP-TCGF  will  not  generate  any GRIMM ET AL.  1837 
ailospecific  lysis. 3 Therefore,  LAK  require  activation  with  a  proliferative  stimulus, 
but they do not appear to require antigenic stimulation as do CTL. 
The final criteria for distinguishing LAK from NK or CTL are those of target cell 
specificity and effector cell phenotype.  Although we do not know if absolutely pure 
populations of NK cells are lytic for solid tumors, we have shown that populations of 
fresh  PBL that  demonstrate  NK  activity  toward  K562  do not  demonstrate  lysis of 
solid  tumors,  suggesting that  the  antigen  recognized on  fresh  tumor cells  is  not  the 
same determinant responsible for NK-mediated lysis of K562 cells. The NK and LAK 
systems are also distinguishable based on the serologic phenotype of the effector cells. 
NK  populations  are  sensitive  to  certain  monocyte  markers  such  as  OKM-1,  and 
resistant to T  cell markers such as OKT.3 (41, 42). We found that LAK do not express 
OKM-1  and do express OKT.3.  The serologic profile of LAK is identical  to that of 
CTL,  but  the  specificity  of lysis  is  clearly  different  in  that  CTL  lyse  target  cells 
expressing the stimulating cell alloantigen.  LAK are observed in populations of CTL 
after allosensitization  (23), but it is not yet known whether these killing functions are 
performed by the same or different cells. Neither the precursors nor the LAK effectors 
are adherent  to plastic or nylon, further ruling out monocytes or B  lymphocytes as 
playing a  role in  the  LAK system.  LAK precursors  are evident  in TDL, which are 
devoid of NK cells, implying that the precursors are not NK cells. 
It is unclear from our data what antigen(s)  is being recognized on fresh solid tumor 
cells.  The  lysis  of allogeneic  tumors  of varying  histologies,  as  well  as  autologous 
tumors, indicates that a "common" antigen is responsible. The determinant recognized 
is neither created nor destroyed by trypsin, and tumors that have not been exposed to 
enzymes are lysed as easily as the treated ones. In results not shown, we also found no 
difference in the lysis of tumors that were cultured overnight before use as target cells, 
indicating that there was no requirement  for a "regrowth" of antigen, as suggested by 
others  (9).  The broad specificity of LAK lysis of all  allogeneic  tumor cells, whether 
cultured  or fresh,  may indicate  that  antigen  recognition  per se is  not  involved, but 
rather some form of nonimmunogenic lectin-like recognition. A  variety of tumor cells 
have recently been described  to express unique lectin-like  molecules on their surface 
(43). A final possibility for the broad specificity oflysis of LAK is that the phenomenon 
may represent  an antibody-mediated  cellular cytotoxicity ADCC effect,  from natu- 
rally  occurring  antibodies  to  tumor  cells  found  in  normal  human  serum.  This 
possibility is highly unlikely, as ADCC effectors may be identical to NK effectors, and 
are found in fresh PBL (for review see 44). 
Further  studies  of the  specificity  of LAK  lysis  are  currently  in  progress  (E.  A. 
Grimm  and  S.  A.  Rosenberg,  manuscript  in  preparation).  It  should  be  noted  that 
autologous  normal  PBL are occasionally lysed by LAK cells,  but  to a  much  lower 
degree than that of tumor, even though both PBL and tumor are equally lysable by 
alIo-CTL (12). 
In conclusion, we have described a  unique cytolytic effector system that is distinct 
from the NK and CTL systems, and that efficiently kills at least  fresh human tumor 
cells from 95% of patients  tested.  The LAK cells are generated  from PBL of normal 
individuals as well as cancer patients and also from thoracic duct lymphocytes devoid 
a Grimm, E. A., A. Mazumder, and S. A. Rosenberg. In vitro growth of cytotoxic human lymphocytes. 
V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in 
vitro sensitization with partially purified T cell growth factor. Manuscript submitted for publication. 1838  LYMPHOKINE-ACTIVATED KILLER CEI,L  PHENOMENON 
of NK cells. The abundant expression ofantitumor cytotoxicity and broad distribution 
of LAK precursor cells makes it a likely candidate for use in adoptive immunotherapy 
and for consideration as an effector mechanism responsible for immune surveillance. 
SumlTlary 
Activation in lectin-free interleukin  2 (IL-2) containing supernatants of peripheral 
blood  mononuclear leukocytes  (PBL)  from  cancer  patients  or  normal  individuals 
resulted  in  expression  of cytotoxicity toward  20 of 21  natural  killer  (NK)-resistant 
fresh solid tumor cells  tested.  Fresh solid tumor cells  were resistant  to NK-mediated 
lysis in  I0 autologous patients' PBL-tumor interactions, and from 17 normal individ- 
uals tested against  13 allogeneic fresh tumors. Culture of PBL in IL-2 for 2-3 d  was 
required for the lymphokine activated killers  (LAK) to be expressed, and lyric activity 
toward  a  variety  of NK-resistant  fresh  and  cultured  tumor  targets  developed  in 
parallel.  Autologous IL-2 was  functional  in  LAK activation,  as  well  as  interferon- 
depleted  IL-2  preparations.  Irradiation  of responder  PBL  before  culture  in  IL-2 
prevented  LAK development.  Precursors of LAK were present  in  PBL depleted  of 
adherent  cells  and  in  NK-void  thoracic  duct  lymphocytes,  suggesting  that  the 
precursor  is  neither  a  monocyte  nor  an  NK  cell.  LAK  effectors  expressed  the 
serologically defined T  cell markers of OKT.'3, Leu-I, and 4F2, but did not express 
the  monocyte/NK marker OKM-I. Lysis of autologous fresh solid tumors by LAK 
from  cancer  patients'  PBL  was  demonstrated  in  85%  of the  patient-fresh  tumor 
combinations. 
Our data  present  evidence that  the  LAK system is  a  phenomenon distinct  from 
either  NK or CTL systems that  probably accounts for a  large number of reported 
nonclassical cytotoxicities. The biological role of LAK cells is not yet known, although 
it  is  suggested  that  these  cells  may  be  functional  in  immune  surveillance  against 
human solid tumors. 
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